title: [Management of renal anemia in 2013].
abstract: Anemia occurs frequently in patients with chronic kidney disease (CKD), especially in the later stages, and the main etiologies are decreased production of erythropoietin (EPO) as well as iron and vitamin deficiencies. For these reasons, it is essential to detect anemia in patients with CKD and to investigate the etiology. If anemia (Hb < 100 g/l) persists after substitution of deficiencies, treatment with recombinant human erythropoietin (rHuEPO) should be considered. New guidelines (KDIGO - August 2012) have just been published by the National Kidney Foundation (NKF) for the management of anemia in patients with renal failure. This article reviews the principles and innovations in management in 2013.
authors.affiliation: Service de médecine interne générale, Département de médecine interne, HUG, 1211 Genève 14. pietro.gianella@hcuge.ch
authors.forename: P
authors.initials: P
authors.lastname: Gianella
authors.forename: P-Y
authors.initials: PY
authors.lastname: Martin
authors.forename: F
authors.initials: F
authors.lastname: Stucker
mesh_terms: D000740:Anemia / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D004921:Erythropoietin / Q000009:adverse effects / Q000172:deficiency / Q000627:therapeutic use; D006801:Humans; D019189:Iron Metabolism Disorders / Q000150:complications / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy*; D008954:Models, Biological; D009398:Nephrology / Q000379:methods / Q000639:trends; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin